跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/NCT00916032
NCT00916032已完成4 期

Pharmacokinetic Comparison of 3000 IU Advate (rAHF-PFM) (Using One 3000 IU Potency Vial) With 3000 IU Advate (rAHF PFM) (Using Two 1500 IU Potency Vials) in Previously Treated Patients With Severe Hemophilia A: a Phase 4, Open-label, Prospective, Randomized, Controlled, Crossover, Multiple Center Study

Baxalta now part of Shire4 个研究点 分布在 2 个国家目标入组 29 人开始时间: 2009年6月29日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
29
试验地点
4
主要终点
Area Under the Plasma Concentration Versus Time Curve From 0 to 48 Hours (AUC 0-48h). Chromogenic Assay
研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The objective of this clinical study is to compare the pharmacokinetic parameters of 3000 IU Advate using one 3000 IU potency vial dissolved in 5 mL diluent with that of 3000 IU Advate using two vials of 1500 IU potency dissolved in 5 mL diluent each (administered in 10 mL diluent in total) in previously treated patients with severe hemophilia A (factor VIII level < 1%).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 65 Years（Adult, Older Adult）
性别
Male
接受健康志愿者
否

入选标准

  • •Participant is 18 to 65 years old, at the time of screening
  • •Participant has provided signed informed consent
  • •Participant has severe hemophilia A, defined by a baseline FVIII level < 1% of normal, as tested at screening at the central laboratory
  • •Participant's weight is between 55-65 kg
  • •Participant was previously treated with FVIII concentrate(s) for a minimum of 150 exposure days prior to study entry
  • •If Participant is HIV positive, he must be immunocompetent as determined with a CD4 count ≥ 200 cells/mm³ (CD4 count at screening)
  • •Participant is willing and able to comply with the requirements of the protocol

排除标准

  • •Participant has a detectable FVIII inhibitor at screening, with a titer ≥ 0.4 Bethesda unit (BU) (Nijmegen modification of the Bethesda Assay) measured at the central laboratory
  • •Participant has a history of FVIII inhibitors with a titer ≥ 0.4 BU (by Nijmegen assay) or ≥ 0.5 BU (by Bethesda Assay) at any time prior to screening
  • •Participant has undergone a surgery within 21 days prior to screening or within 6 weeks prior to the anticipated first pharmacokinetics(PK) infusion
  • •Participant has an abnormal renal function (serum creatinine > 1.5 mg/dL)
  • •Participant has active hepatic disease (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels >5 times the upper limit of normal)
  • •Participant has severe chronic liver disease as evidenced by, but not limited to, any of the following: International Normalized Ratio (INR) > 1.4, hypoalbuminemia, portal vein hypertension including presence of otherwise unexplained splenomegaly, and history of esophageal varices
  • •Participant has clinical and/or laboratory evidence of abnormal hemostasis from causes other than hemophilia A (eg, late-stage chronic liver disease, immune thrombocytopenia purpura)
  • •Participant is currently receiving, or is scheduled to receive during the course of the clinical study, an immunomodulating drug other than anti-retroviral chemotherapy (eg, alfa-interferon, or corticosteroid agents at a dose equivalent to hydrocortisone greater than 10 mg/day)
  • •Participant has a known hypersensitivity to mouse or hamster proteins
  • •Participant has participated in another clinical study involving an investigational product or investigational device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving an investigational product or investigational device during the course of this clinical study
  • •Participant is identified by the investigator as being unable or unwilling to cooperate with study procedures
  • •Participant is a member of the team conducting this clinical study or is in a dependent relationship with one of the study team members. Dependent relationships include close relatives (ie, children, partner/spouse, siblings, or parents) as well as employees of the investigator or site personnel conducting the clinical study.

结局指标

主要结局

Area Under the Plasma Concentration Versus Time Curve From 0 to 48 Hours (AUC 0-48h). Chromogenic Assay

时间窗: Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours.

Computed using the linear trapezoidal method.

Area Under the Plasma Concentration Versus Time Curve From 0 to 48 Hours (AUC 0-48h). One-stage Activated Partial Thromboplastin Time (aPTT) Assay

时间窗: Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours.

Computed using the linear trapezoidal method.

次要结局

  • Area Under the Plasma Concentration Versus Time Curve From 0 to Infinity (AUC 0-infinity). Chromogenic Assay(Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours.)
  • Incremental Recovery at Cmax - Chromogenic Assay(Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3 hours.)
  • Incremental Recovery at Cmax - One-stage aPTT Assay(Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3 hours.)
  • Incremental Recovery at 30 Minutes- One-stage aPTT Assay(30 minutes pre-infusion and 30 minutes post-infusion)
  • FVIII Clearance- Chromogenic Assay(Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours.)
  • Mean Residence Time (MRT)- Chromogenic Assay(Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours.)
  • Volume of Distribution at Steady State- Chromogenic Assay(Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours.)
  • Incremental Recovery at 30 Minutes- Chromogenic Assay(30 minutes pre-infusion and 30 minutes post-infusion)
  • FVIII Clearance- One-stage aPTT Assay(Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours.)
  • Volume of Distribution at Steady State- One-stage aPTT Assay(Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours.)
  • Factor VIII (FVIII) Maximum Plasma Concentration (C-max)- One-stage aPTT Assay(Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours.)
  • Factor VIII (FVIII) Maximum Plasma Concentration (C-max)- Chromogenic Assay(Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours.)
  • Area Under the Plasma Concentration Versus Time Curve From 0 to Infinity (AUC 0-infinity). One-stage aPTT Assay(Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours.)
  • Mean Residence Time (MRT)- One-stage aPTT Assay(Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours.)
  • Elimination Phase Half-life- One-stage aPTT Assay(Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours.)
  • Elimination Phase Half-life- Chromogenic Assay(Within 30 minutes prior to the start of the infusion; and after the end of the infusion at 15, 30 minutes, and 1, 3, 6, 9, 24, 28, 32, and 48 hours.)

研究者

发起方
Baxalta now part of Shire
申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验

已完成
4 期
Pharmacokinetic Comparison of Advate rAHF-PFM With Recombinate rAHF in Patients With Severe Hemophilia AHemophilia A
NCT00666406Baxalta now part of Shire9
进行中（未招募）
不适用
Advate (rAHF-PFM): Pharmacokinetic comparison of 3000 IU Advate (rAHF-PFM) (using one 3000 IU potency vial) with 3000 IU Advate (rAHF-PFM) (using two 1500 IU potency vials) in previously treated patients with severe hemophilia A: a Phase IV, open-label, prospective, randomized, controlled, crossover, multiple center study - Advate 3000severe hemophilia AMedDRA version: 9.1Level: LLTClassification code 10060612Term: Hemophilia A
EUCTR2008-007347-13-BGBaxter Innovations GmbH23
撤回
4 期
Study Comparing Blood Levels of ReFacto and Advante in Hemophilia AHemophilia A
NCT00168051Wyeth is now a wholly owned subsidiary of Pfizer
已完成
4 期
China ADVATE PTP StudyHemophilia A
NCT02170402Baxalta now part of Shire82
已完成
1 期
Clinical Trial to Compare the Pharmacokinetics and Pharmacodynamics After Oral Administration of Glucophage and HL-018Healthy
NCT01232036Asan Medical Center28